Introducing Multiplex and High Sensitivity Immunoassays for Characterization of SARS-CoV-2 Humoral Immunity


D Garcia-West1


Our scientists have developed several MILLIPLEX®
and Single Molecule Counting (SMC™) based SARS-CoV-2-specific immunoassay
kits in response to the COVID-19 research community’s growing needs for
research tools used to further our understanding of the novel coronavirus. These
qualitative Research Use Only (RUO) assays, which can detect antibodies against
SARS-CoV-2 antigens in human serum or plasma samples, are intended to empower
researchers performing vaccine efficacy, epidemiology, and population
studies.  Our new MILLIPLEX® SARS-CoV-2
panels can facilitate simultaneous detection of the SARS-CoV-2 Spike S1, Spike
S2, Receptor Binding Domain (RBD), and Nucleocapsid (N) proteins
antigen-specific IgM, IgG, or IgA antibody responses on the Luminex®
multiplex platform. They are well suited for examining the immune response to the virus over the
course of infection and recovery from COVID-19.  Meanwhile, our SMC™ SARS-CoV-2 kits offer the ability
to characterize viral antigen specific humoral immunity with greater
, such as in cases involving acute infections and subclinical immune
.  For these new assays, data
are presented from human patient samples sets confirmed positive or negative
for COVID-19 by SARS-CoV-2 PCR tests. 
Overall, our new MILLIPLEX® and SMC™ assays can assist in
COVID-19 research efforts to help society overcome the current global pandemic.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021